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Abstract
Introduction A number of studies have reported an
association between peripheral hearing impairment,
central auditory processing and Alzheimer’s disease
(AD) and its preclinical stages. Both peripheral hearing
impairment and central auditory processing disorders are
observed many years prior to the clinical manifestation
of AD symptoms, hence, providing a long window of
opportunity to investigate potential interventions against
neurodegenerative processes. This paper outlines the
protocol for a systematic review of studies examining
the central auditory processing functions in AD and its
preclinical stages, investigated through behavioural
(clinical assessments that require active participation)
central auditory processing tests.
Methods and analysis We will use the keywords and
Medical Subject Heading terms to search the following
electronic databases: MEDLINE, PsychINFO, PubMed,
Scopus, EMBASE and CINAHL Plus. Studies including
assessments of central auditory function in adults
diagnosed with dementia, AD and its preclinical stages that
were published before 8 May 2019 will be reviewed. This
review protocol will be reported according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Protocols guidelines. Data analysis and search results will
be reported in the full review. This manuscript has designed
the protocols for a systematic review that will identify the
behavioural clinical central auditory processing measures
that are sensitive to the changes in auditory function in
adults with AD and its preclinical stages. Such assessments
may subsequently help to design studies to examine
the potential impact of hearing and communication
rehabilitation of individuals at risk of AD.
Ethics and dissemination Ethical approval is not
required as this manuscript only reports the protocols
for conducting a systematic review as primary data
will only be reviewed and not be collected. The results
of this systematic review will be disseminated through
publication and in scientific conferences.
PROSPERO registration number CRD42017078272.

Introduction
Globally, about 44 million people were living
with Alzheimer’s disease (AD) or related

Strengths and limitations of this study
►► The systematic review, this protocol outlines, will

contribute to strengthen the understanding of the
strengths and limitations of behavioural central
auditory function assessments in individuals with
Alzheimer’s disease (AD) and those at risk of developing AD.
►► This systematic review protocol is described in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocols
guidelines.
►► There are no language restrictions imposed for the
full-text literature search for this systematic review.
►► Exclusion of articles with abstracts not in English can
potentially mean that important findings are missed.
►► The manuscript only describes a protocol for a systematic review. A follow-up manuscript will explore
the systematic review results and meta-analysis of
the data.

dementia in 2017 and this number is projected
to reach 76 million by 2050.1 The preclinical
and prodromal stages of AD include subjective cognitive decline (SCD), mild cognitive
impairment (MCI) and dementia.2–4 Not
all those with SCD or MCI may progress to
AD, only a certain per cent of individuals will
proceed to the next neurodegenerative stage.5
The neuropathological changes associated
with AD have been shown to start up to 20
years prior to the clinically manifested symptoms.6 This long pre-clinical phase provides
a rare opportunity for early detection and
prevention of the disease, and it is now estimated that up to 35% of AD diagnoses worldwide could be delayed or prevented with early
intervention and by making lifestyle changes
whichthat reduce the identified modifiable
risk factors for developing AD.7 8 Identifying
these early markers of AD as well as the potential factors which will help prevent or delay
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both age-related and pathological cognitive declines in
AD becomes particularly important considering there is
no cure or effective treatment currently insight.
According to Lancet International Commission on
Dementia Prevention, Intervention, and Care report,
mid-life hearing loss could account for 9% of the population attributable fraction of modifiable risk factors associated with increased risk of AD.7 The auditory system is
comprised of two key components, the peripheral hearing
system (outer, middle and inner ear and auditory nerve)
and the central auditory pathway (cochlear nucleus to the
auditory cortex), which are respectively involved in the
detection and processing of incoming auditory signal.9
The central auditory system is responsible for key communication skills such as feature extraction and detecting
small gaps in speech, which is crucial in speech discrimination and integrating and separating binaural auditory
information.10 11 A combination of these central auditory
processing (CAP) skills facilitates the understanding of
speech in background noise and spatial processing skills
as well as language and information processing.10 11
Results from longitudinal studies suggest that CAP
skills, in the absence of a severe peripheral hearing loss,
are associated with high incidences of cognitive decline
and AD dementia.12–14 These studies have demonstrated
that those with severe CAP disorders (<50% scores on
Dichotic Sentence Identification task) were at a greater
risk for incident dementia with hazard ratios of 9.9 (95%
CI 3.6 to 26.7).13
Further, a number of studies have reported impaired
CAP skills in individuals with MCI.13 15 16 The exact mechanism underlying the impaired CAP skills and cognitive
decline is yet to be elucidated, two theories have been
proposed to explain this association. The first theory
suggests that it could result from independent decline
in both CAP skills and cognition, exhausting cognitive
reserve and exacerbating the deficits experienced in both
CAP skills and cognitive abilities, manifesting as language,
learning and communication difficulties.11 The second
theory suggests that cortical degeneration of common
neuronal structures, resulting from neurodegenerative
disorders such as dementia and AD, could lead to deficits
in speech, hearing and cognitive processes.12 17
Numerous studies to date have concluded that there
is a strong link between poor central auditory functions
and the preclinical stages of AD. This link could provide
a unique opportunity to easily identify people at high
risk of developing, or who are in the preclinical phases
of AD, years before a formal diagnosis can be made. 1819
Based on existing meta-analyses data, Norton et al8 calculated the population attributable risk of AD worldwide,
UK, USA and Europe for seven modifiable risk factors
that have been associated with AD: diabetes, midlife
hypertension, midlife obesity, physical inactivity, depression, smoking and low educational attainment. Based
on the assumption of a causal relationship between AD
and risk factors and timely intervention, the effect of risk
factor reductions on AD projections from 2010 to 2050
2

for each of the seven risk factors was calculated. Results
suggested that if the risk factor was reduced by 10% or
20% per decade for each of the seven risk factors, the
projected cases of worldwide AD could be reduced by 8.3
to 16.2 million by 2050.8 It is important that we evaluate
the validity and reliability of the central auditory function
tests used in preclinical AD (SCD, MCI and dementia)
before proceeding to develop tests or intervention strategies for people identified to have poor CAP skills.
This paper outlines the protocol that will be used to
systematically review the behavioural central auditory
function assessments of 40–85-
year-
old people diagnosed with AD and its preclinical stages and compares
the results with the 40–85-year-old healthy adults with
no cognitive impairment or memory complaints. The
systematic review will also examine the (1) challenges
pertaining to selection and administration of behavioural
CAP assessments to those with impaired cognitive and/or
daily living functions, (2) modifications to the standard
central hearing assessment procedures to accommodate
impaired cognitive and/or daily living functions and
(3) the factors that influence the interpretation of test
results. Two research questions will be investigated: (1)
What are the most commonly utilised behavioural CAP
tests for older adults diagnosed with AD or in preclinical
stages and (2) What are the limitations of these measures
and how can they be improved?
Methods and analysis
This protocol will be reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols 2015 checklist.20
Patient and public involvement
This was a protocol paper for reviewing previously
published papers. Therefore, no patient or patient-
related data were required, assessed or involved in any
part of this protocol preparation.
Criteria
All papers related to behavioural central auditory functions and AD dementia, MCI and SCD that were published
and available on searched databases before 8 May 2019
will be considered. The inclusion and exclusion criteria
are described below.
Population
Adults aged between 40 and 85 years with typical ‘amnestic
MCI, dementia due to AD, non-amnestic MCI and SCD’
will be included. Other cognitive impairments not related
to AD, including logopenic progressive aphasia, primary
progressive aphasia, posterior cortical atrophy and frontal
variant AD, will be excluded. Participants with visual
impairment also will be excluded.
Intervention
Behavioural central auditory function tests that measure
(1) monaural low redundancy speech tests (low-
pass
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filtered speech tests, speech-
in-
noise tests, speech-
in-
message competition tests, time-
compressed speech
tests), (2) temporal processing (temporal ordering or
sequencing, temporal resolution or discrimination,
temporal integration or summation, temporal masking),
(3) binaural interaction (masking-level difference, interaural timing and lateralisation/localisation, binaural
fusion, rapidly alternating speech perception) and (4)
dichotic listening (dichotic digits, dichotic sentences,
staggered spondaic word test, dichotic consonant–vowels,
dichotic rhymes) will be included. Auditory electrophysiological assessments will be excluded from the review.
Comparator
The control group will consist of healthy adults aged from
40 to 85 years. Those with cognitive complaints, neurocognitive impairment, impaired daily living functions and
visual impairment will be excluded.
Outcomes
Only quantitative measurements will be included. Both
cross-sectional and longitudinal studies that documented
the changes of the central auditory functions of adults
diagnosed AD and its preclinical stages will be included.
Study type
Randomised controlled trials, feasibility studies, pilot
studies and clinical trials will be considered.
No language restrictions will be imposed during the literature search, however, the abstract should be available in

English. All studies should be original research published
in a peer-reviewed journal.
Information sources
The following databases will be selected: MEDLINE,
PsychINFO, PubMed, Scopus, EMBASE and CINAHL
Plus electronic databases, which are the most likely to
index reports of studies in audiology, speech and hearing,
psychology, cognition, neuroscience, neuropsychology
and cognitive sciences, psychiatry and mental health. A
hand-search of references of the included articles will also
be performed as well. Grey literature will be sought using
Google Scholar, Open Grey, ClinicalTrials.gov and International Clinical Trials Registry Platform. Unpublished
studies from conference proceedings, scientific meetings
or thesis were included in the search to mitigate publication bias.
Search strategy
To maximise the sensitivity of the search strategy, the
following will be used: MeSH terms in exploded mode
(MEDLINE, PsychINFO and EMBASE), text searches or
keywords (PubMed, CINAHL Plus and Scopus), with truncations, synonyms and different spellings. The searches
will be conducted in the title, abstract and full-text fields.
Each combination of identifiers between domains will be
searched when occurring concurrently in the same report
(refer to table 1).

Table 1 Keywords and Medical Subject Headings (MeSH) terms (explode) applied per domain in search databases
Domain

Keywords

MeSH terms

Central
auditory
tests

Central hearing OR central hearing loss OR central hearing impairment OR central
hearing decline OR central presbycusis OR auditory processing OR central auditory
processing OR central auditory deficit* OR auditory processing disorder* OR speech-
in-noise OR gaps-in-noise OR dichotic processing OR dichotic digit test* OR dichotic
word listening test* OR dichotic sentence test* OR dichotic sentence identification
test* OR DSI* OR dichotic CV* OR dichotic rhymes OR staggered spondaic word test*
OR synthetic sentence identification OR competing sentences OR SSI* OR temporal
processing OR temporal resolution OR temporal pattern test* OR frequency pattern
test* OR pitch pattern test* OR duration pattern test* OR temporal discrimination OR
frequency discrimination OR pitch discrimination OR masking level difference OR
MLD* OR gap detection OR gap discrimination OR gaps in noise OR GIN* OR random
gap detection test* OR RGDT* OR adaptive test of temporal resolution OR ATTR*
OR temporal integration OR temporal masking OR binaural interaction OR binaural
separation OR binaural integration OR lateralization OR lateralization OR localization
OR localization OR inter-aural time differences OR inter-aural time difference OR
ITD*OR order identification OR temporal masking OR inter-aural intensity difference
OR inter-aural intensity difference OR IID* OR spatial processing OR rapidly alternating
speech perception OR RASP* OR listening in spatialized noise OR LisN* OR listening
in spatialized noise-continuous discourse test OR LISN-CD* OR listening in spatialized
noise-sentences test OR LISN-S*
Alzheimer* disease OR Alzheimer’s* OR Dementia OR AD OR cognitive impairment OR
cognitive decline OR cognitive processing OR cognitive ability dementia OR Alzheimer*
type dementia OR mild cognitive impairment OR MCI OR amnestic MCI OR amnestic
mild cognitive impairment OR minimal cognitive impairment OR moderate cognitive
impairment OR severe cognitive impairment OR memory complainers OR SMC OR
subjective cognitive decline OR SCD, or cognitive impairment no dementia OR CIND

Hearing Loss OR
Central Auditory
diseases OR Auditory
perception

Alzheimer’s
disease
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In order to account for all the behavioural central auditory hearing assessments that were not covered by the
keywords and MeSH terms, we will also include any test
that measures monaural low redundancy speech/tones,
dichotic listening tests consist of musical notes/chords,
temporal processing and binaural interaction tasks.
A dual independent review will be applied to the search
strategy as well as to the processes of identification and
assessment of studies to reduce random errors and bias.21
The search strategy will also be reviewed by an independent librarian.22
Data management
All results from database and hand searches will be
exported into EndNote V.X7 software (Thomson Reuters
2016) and then into the Covidence software program for
systematic reviews (www.covidence.org). All the selected
articles will then be independently screened using the
Covidence software program.
Study selection
After removing the duplicates, titles and abstracts will be
analysed against the study eligibility criteria (HYT and
HM). Papers without abstract or abstracts that lack information will be kept for full-text analysis. The manuscripts
kept for full-text analysis will be also screened by a third
researcher (DMPJ). Discrepancies will be resolved by
consensus. Reference lists and citations of the included
papers and grey literature will be analysed to identify
other potentially relevant papers (DMPJ).
Data extraction
The information extracted from screened articles will
include the following (1) authors of the paper, year of
publication and journal, (2) geographical location of
the study, (3) demographics of the participants, (4) aims
of the study, (5) types of the tests used, (6) outcomes
measured, (7) major findings (results/conclusions), (8)
limitations or difficulties. If data are not clearly presented
in the research article, the authors of the original article
will be contacted via email for further clarifications. Data
will be reported under four subgroups: normal cognitive
functions (controls), AD, MCI and SCD.
Quality assessment
The included studies will be assessed (internal validity
or reliability) to address the following risk of bias: (1)
selection bias, (2) performance bias, (3) detection bias,
(4) attrition bias, (5) analysis bias and (6) reporting bias
will be observed. A quality assessment tool developed by
Thomas et al. 23 will be used to systematically evaluate
the methodological quality of the quantitative study
designs. The findings will be analysed and a table of
evidences will be constructed to grade the recommendations based on American Society of Plastic Surgeons’
(ASPS) Evidence Rating Scale for Therapeutic Studies
24
scale for grading recommendations.
4

Meta-analytic approach
The meta-analysis will be conducted using the Comprehensive Meta-Analysis (CMA V.3, Biostat, Englewood,
USA). The synthesised effect size will be reported as the
standard difference in mean with 95% CI. The standard
mean difference indicates the difference between the
means of two groups divided by their pooled SD. The
data for the meta-analysis will be entered as continuous
outcomes under the random effects model to account
for variations between study methodologies. Heterogeneity will be assessed using the Q-value statistic and the
I2 statistic to indicate heterogeneity as a percentage. A
p value <0.05 will be considered statistically significant
for all analyses.

Discussion
The main aim of this study is to systematically review
the behavioural central auditory function assessments
that have been used in studies with participants diagnosed with AD or in its preclinical stages. The results of
the review will provide information about behavioural
central auditory measures that are sensitive to the
changes in auditory function in older adults with AD
and its preclinical stages. This will help to design clinical trials to examine the potential impact of hearing
and communication rehabilitation for individuals at
risk of AD. We postulate that this review will be useful
to a variety of stakeholders who have an interest in the
care of AD and related disorders.
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